2023-03-13Zeitschriftenartikel
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
Stoliaroff-Pepin, Anna
Peine, Caroline
Herath, Tim
Lachmann, Johannes
Hellenbrand, Wiebke
Perriat, Delphine
Dörre, Andreas
Michel, Janine
Grossegesse, Marica
Hofmann, Natalie
Rinner, Thomas
Kohl, Claudia
Brinkmann, Annika
Meyer, Tanja
Stern, Daniel
Treindl, Fridolin
Dorner, Brigitte G.
Hein, Sascha
Werel, Laura
Hildt, Eberhard
Gläser, Sven
Schühlen, Helmut
Isner, Caroline
Peric, Alexander
Ghouzi, Ammar
Reichardt, Annette
Janneck, Matthias
Lock, Guntram
Huster, Dominik
Grünewald, Thomas
Schaade, Lars
Wichmann, Ole
Harder, Thomas
Purpose:
COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave.
Methods:
We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates.
Results:
21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses.
Conclusion:
Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.
Dateien zu dieser Publikation